Published in Biochem Pharmacol on May 06, 2010
A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol (2013) 1.03
Model peptides provide new insights into the role of histidine residues as potential ligands in human cellular copper acquisition via Ctr1. J Am Chem Soc (2011) 1.01
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain. Proc Natl Acad Sci U S A (2013) 0.96
Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Targets (2015) 0.85
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics (2014) 0.85
Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). J Trace Elem Med Biol (2013) 0.80
Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochem Pharmacol (2014) 0.79
Differential Natural Selection of Human Zinc Transporter Genes between African and Non-African Populations. Sci Rep (2015) 0.77
Cathepsin Protease Controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-binding Ectodomain. J Biol Chem (2016) 0.76
Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. J Biol Inorg Chem (2017) 0.75
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol (2008) 4.03
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J (1996) 3.04
Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem (2002) 2.24
Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci U S A (2001) 2.19
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci U S A (2001) 1.90
Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem (2002) 1.89
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Three-dimensional structure of the human copper transporter hCTR1. Proc Natl Acad Sci U S A (2009) 1.79
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
Projection structure of the human copper transporter CTR1 at 6-A resolution reveals a compact trimer with a novel channel-like architecture. Proc Natl Acad Sci U S A (2006) 1.66
Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene (2000) 1.64
Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase. Proc Natl Acad Sci U S A (2003) 1.62
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
The mechanism of copper uptake mediated by human CTR1: a mutational analysis. J Biol Chem (2005) 1.50
Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J Biol Chem (2004) 1.50
Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem (2002) 1.49
Eukaryotic CTR copper uptake transporters require two faces of the third transmembrane domain for helix packing, oligomerization, and function. J Biol Chem (2004) 1.44
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem J (2008) 1.29
Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem (2007) 1.27
Copper homeostasis in eukaryotes: teetering on a tightrope. Biochim Biophys Acta (2006) 1.26
Maintaining copper homeostasis: regulation of copper-trafficking proteins in response to copper deficiency or overload. J Nutr Biochem (2004) 1.24
Crystal structures of cisplatin bound to a human copper chaperone. J Am Chem Soc (2009) 1.23
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res (2009) 1.22
A structural perspective on copper uptake in eukaryotes. Biometals (2007) 1.20
Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol (2009) 1.19
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
Copper deficiency. Curr Opin Gastroenterol (2007) 1.10
The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem (2004) 1.03
Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1. J Biol Inorg Chem (2009) 0.92
The cellular pharmacology of oxaliplatin resistance. Eur J Cancer (2002) 0.91
Interaction of cisplatin and analogues with a Met-rich protein site. J Biol Inorg Chem (2008) 0.89
Interaction between platinum complexes and a methionine motif found in copper transport proteins. Angew Chem Int Ed Engl (2007) 0.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res (2002) 1.98
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther (2005) 1.89
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res (2003) 1.79
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
Porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. ACS Nano (2011) 1.61
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol (2002) 1.56
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2004) 1.53
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res (2004) 1.49
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol (2004) 1.41
Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res (2009) 1.37
Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol (2007) 1.30
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res (2005) 1.30
DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res (2004) 1.24
Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res (2004) 1.23
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res (2009) 1.22
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol (2003) 1.20
Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem (2008) 1.16
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem (2006) 1.12
In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles. Nat Commun (2013) 1.11
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res (2006) 1.10
The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol (2003) 1.10
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol (2002) 1.10
Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer (2010) 1.10
Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (2012) 1.09
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther (2006) 1.09
Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2010) 1.06
Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol (2003) 1.06
The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem (2004) 1.03
Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (2006) 1.03
Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol (2009) 1.02
Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochem Pharmacol (2012) 1.02
Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat (2006) 1.02
Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol (2009) 1.01
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol (2010) 1.00
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. Int J Nanomedicine (2010) 1.00
DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res (2006) 0.99
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol (2009) 0.99
Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol (2005) 0.99
Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol (2005) 0.98
Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol (2006) 0.98
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther (2009) 0.97
An all-atom model of the structure of human copper transporter 1. Cell Biochem Biophys (2012) 0.95
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol (2007) 0.95
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. PLoS One (2013) 0.94
cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol (2004) 0.93
The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol (2010) 0.93
CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm (2010) 0.93
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther (2011) 0.92
The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J Inorg Biochem (2012) 0.91
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol (2005) 0.89
Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics (2014) 0.88
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol (2012) 0.88
Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery. Bioconjug Chem (2007) 0.88
Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (2011) 0.87
Characterization of a clinical polymer-drug conjugate using multiscale modeling. Biopolymers (2010) 0.87
Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol (2012) 0.86
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer (2011) 0.84
Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets (2014) 0.83
Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Mol Pharmacol (2008) 0.83
Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol (2006) 0.83
The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics (2013) 0.82
Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water. J Am Chem Soc (2014) 0.81
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother Pharmacol (2011) 0.80
Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Mol Pharmacol (2012) 0.80
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol (2009) 0.79
Aggregation properties of a polymeric anticancer therapeutic: a coarse-grained modeling study. J Chem Inf Model (2011) 0.79
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.79